Chiron Real Estate stock
XRNNYSEChiron Real Estate Inc., Real EstateISIN US37954A3032
46Score 46 out of 100, Weak
Price and trend
30 / 100
Price history
−23% since 2026The chart shows daily closing prices since 27 Jan 2026, adjusted for stock splits and excluding dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 23% below it.
Normal: the price is neither overheated nor sold off (RSI 35).
The price is 29% below its 52-week high. Largest decline since 27 Jan 2026: 30% (July 2026 to November 2026).
Chart figures for advanced users
- SMA 50$32.98
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$35.05
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)35
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$26.65
- The lowest closing price of the last twelve months.
- Resistance$38.10
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Chiron Real Estate Inc. belongs to the REIT (Healthcare Facilities) industry (United States) and, with a market value of $357.26M, is number 18 of 18 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $161.03M (up 16.3% year on year) and a loss of $12.12M.
- For fiscal 2026, analysts expect on average revenue of $145.98M (down 9.3%) and adjusted earnings per share of $3.00 (up 383.2%).
Show more
- MEQIRI Score 46 out of 100 (Weak): rank 253 of 327 in Real Estate, median 55.
- For real estate investment trusts (REITs) what counts is funds from operations (FFO and AFFO). The P/E and the payout ratio of earnings say little here, because depreciation on properties depresses earnings.
- Our model puts fair value at $61.44, with the price 56% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High dividend yieldDividend yield 8.53%, REIT (Healthcare Facilities) median 5.5%.
- High marginNet margin 32.7% over the last 12 months, REIT (Healthcare Facilities) median 6.6%.Profitability 50
Weaknesses
- Analysts expect falling earningsDown 111.6% a year through 2027 (estimates from 2 analysts).Growth 58
- Interest barely coveredOperating profit covers interest only 0.8 times.Stability 56
- Negative free cash flowFree cash flow −$188.56M over the last 12 months.Fundamentals 27
Its standout strength is valuation, while fundamentals and momentum hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
Possible value trapIn our model the price counts as cheap below $47.26 and expensive above $87.77 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $58.39 (cash-flow model) and $64.49 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $56.71, at 7.8% it would be $68.53.
Possible value trap: looks cheap, but score below 50, weak balance sheet.
Valuation metrics
Half from the cash-flow model, half from FFO per share times the median price to FFO of the REIT industry (16.9). For REITs, depreciation on buildings depresses earnings, so FFO counts instead of earnings, here following the industry rule (Nareit) from the filings with the SEC: gains on property sales are deducted where the company reports them in the standard items. The cash-flow model uses AFFO: operating cash flow less maintenance, estimated at 4% of revenue, and less preferred dividends. New construction and acquisitions do not count as running costs there.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 1.2% on the twelve months before. Revenue has grown strongly since 2015, at around 55% per year. From 2015 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 6%, operating 31%, net −8%. Last 12 months: net 33%. From 2015 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 24 Feb 2027in 104 days
- Last reported
- 4 Nov 2026EPS reported −$0.67 (expected −$0.49)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $3.000.0%
- Revenue
- $145.98M−0.9%
- Earnings per share
- −$2.010.0%
- Revenue
- $143.15M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +2.9%Same-store NOI growth of 1.7% is in line with the guidance issued at the start of the year, no change is stated.
“During the quarter, same-store NOI increased 1.7% on a normalized basis, which is in line with our expectations and the same-store guidance we issued at the beginning of the year.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
4 insiders bought on the open market between 10 Aug 2026 and 17 Aug 2026, $2.58M in total.
- Whitlock Matthew FitzsimmonsPurchase
17 Aug 2026, Chief Investment Officer
- Shares
- 500
- Price
- $36.38
- Value
- $18,190
- Whitlock Matthew FitzsimmonsPurchase
14 Aug 2026, Chief Investment Officer
- Shares
- 500
- Price
- $37.21
- Value
- $18,605
- Roseth Aaron RobertPurchase
12 Aug 2026, COO
- Shares
- 13,500
- Price
- $36.73
- Value
- $495,855
Show 6 more
- Decker Mark Okey JrPurchase
11 Aug 2026, CEO and President
- Shares
- 6,875
- Price
- $35.92
- Value
- $246,950
- Decker Mark Okey JrPurchase
11 Aug 2026, CEO and President
- Shares
- 550
- Price
- $36.00
- Value
- $19,800
- Fitzgerald CharlesPurchase
11 Aug 2026, Board
- Shares
- 14,000
- Price
- $35.78
- Value
- $500,920
- Decker Mark Okey JrPurchase
10 Aug 2026, CEO and President
- Shares
- 8,000
- Price
- $35.88
- Value
- $287,040
- Fitzgerald CharlesPurchase
10 Aug 2026, Board
- Shares
- 27,600
- Price
- $35.94
- Value
- $991,944
- Cypher MatthewPurchase
14 May 2026, Board
- Shares
- 1,420
- Price
- $35.12
- Value
- $49,874
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Chiron Real Estate
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
327 rated companies in Real Estate
- This company
- 46
- Sector median
- 55
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in REIT (Healthcare Facilities)
The next larger companies by market value
- National Health InvestorsNHI $3.24B61
- LTC PropertiesLTC $2.47B71
- Diversified Healthcare TrustDHC $1.78B32
- National Healthcare Properties, Inc. (NHP)NHP $1.14B41
- Medical Properties TrustMPT $1.06B40
- Care Property InvestCPINV.BR $603.96M65
- Universal Health Realty Income TrustUHT $542.5M61
- Community Healthcare TrustCHCT $431.38M56
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak since 10 Nov 2026, previously Neutral
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.